Pars Tarava’s Electrochemotherapy Technology Showcased in National Media
As featured in Alef News, Pars Tarava stands at the forefront of Iran’s biomedical technology landscape. Founded through research initiatives at Tarbiat Modares University in 2005 and formally established in 2018, our company has revolutionized cancer treatment through proprietary electroporation and electrochemotherapy technologies.
Global Recognition Through Innovation
We take pride in being recognized as the global leader in electroporation systems, joining the ranks of esteemed institutions such as Harvard University, Bio-Rad, and Eppendorf. Today, as the sole manufacturer in the MENA region, our devices empower leading Iranian research laboratories, genetic centers, and pharmaceutical facilities, significantly reducing technological dependencies.
Transforming Cancer Treatment
Our flagship achievement – Iran’s first electrochemotherapy device with patented treatment protocols – represents a breakthrough in oncology care. By combining controlled electrical pulses with chemotherapy drugs, our technology:
- Enhances drug absorption in cancerous cells by 5-8x
- Reduces treatment costs by 60% compared to conventional therapies
- Minimizes side effects through localized, low-dose applications
Clinically validated protocols show 80% efficacy for resistant tumors including skin, head/neck, and breast cancers, with ongoing Phase III trials for deep-tissue sarcoma treatment.
Dual Impact Across Medicine
Beyond human oncology, we’ve pioneered veterinary applications that are transforming animal care:
- Successfully treated malignant tumors in companion animals
- Developed species-specific protocols for dogs, cats, and horses
- Replaced high-risk surgeries with outpatient procedures
Notable cases include complete remission of 6cm oral tumors in cats without bone resection.
The Road Ahead
With 12 patents secured and IRCT-registered trials advancing, we continue to:
- Develop next-generation deep-tissue treatment systems
- Expand international partnerships across Asia and Europe
- Create integrated solutions combining electrochemotherapy with immunotherapy
Our vision remains clear: establishing Iran as a global hub for accessible, advanced cancer care technologies.
